GlassScriptPhysician profile
Michael A Pahl
NPI 1619094208
$7,580.60
in general payments reported to CMS, 2019-2025
27 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2021: $1,534 · 2022: $2,400 · 2023: $2,348 · 2024: $692 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Travel and Lodging: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.70 |
| Travel and Lodging | $1,244.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exactech, INC. | $3,416.95 | 2019-2022 | |
| Smoky Mountain Surgical LLC | $1,204.64 | 2023-2025 | |
| Stryker Corporation | $770.33 | 2021-2024 | Blueprint Patient Specific Instrumentation, 1788, Iconix |
| Arthrex, INC. | $730.61 | 2021-2023 | |
| Smith+Nephew, INC. | $460.26 | 2022-2025 | Healicoil, Q-Fix, Real Intelligence |
| Alpha Orthopedic Systems | $214.64 | 2021-2022 | |
| Avanos Medical | $141.86 | 2021 | |
| Depuy Synthes Sales INC. | $125.04 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $95.95 | 2021-2025 | Zilretta, Exparel |
| Organogenesis INC. | $60.08 | 2022-2025 | Simplimax |
| Pacira Therapeutics, INC. | $34.04 | 2021 | |
| Endo USA, INC. | $33.72 | 2024-2025 | Xiaflex |
| Zimmer Biomet Holdings, INC. | $30.86 | 2021 | |
| Endo Pharmaceuticals INC. | $28.52 | 2022-2023 | Xiaflex |
| Kowa Pharmaceuticals America, INC. | $27.49 | 2023 | Seglentis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $24.72 | 2025 | Irrisept |
| Linvatec Corporation | $23.62 | 2019 | |
| Mallinckrodt Enterprises LLC | $20.95 | 2019 | |
| Fidia Pharma USA INC. | $19.94 | 2023 | Triluron, Hymovis |
| Orthofix Medical, INC. | $19.29 | 2023 | Physio-Stim |
| Abbott Laboratories | $17.98 | 2021 | |
| Vericel Corporation | $15.22 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $15.07 | 2024 | |
| Davol INC. | $14.58 | 2023 | Channel Drain |
| Horizon Therapeutics Plc | $13.67 | 2021 | |
| Heraeus Medical, LLC. | $10.32 | 2021 | |
| Heron Therapeutics, INC. | $10.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.